Literature DB >> 17966011

No positive effects of OP-1 device on the incorporation of impacted graft materials after 8 weeks: a bone chamber study in goats.

Gerjon Hannink1, B Willem Schreurs, Pieter Buma.   

Abstract

BACKGROUND: Bone morphogenetic proteins (BMPs) have the potential to improve clinical outcome after hip revision surgery by improving graft incorporation and implant fixation. However, impaction of cancellous bone grafts and TCP/HA bone substitute mixed with OP-1 device in a bone chamber in goats in a previous study led to reduced fibrous tissue ingrowth after 4 weeks. New bone formation was not promoted by OP-1. In the current study we examined whether this reduction represented a final loss of ingrowth or was just a delay, and whether the reduction can be overcome and ultimately results in a better late ingrowth.
METHODS: Bone chambers with impacted allografts and impacted TCP/HA granules mixed with 2 doses of OP-1 device were implanted in proximal medial goat tibias. Impacted allografts and TCP/HA not treated with OP-1 served as controls. After 8 weeks, the incorporation was evaluated using histology and histomorphometry.
RESULTS: Histology revealed evidence of bone graft incorporation, which proceeded in a similar way in both allografts and TCP/HA, with and without the addition of OP-1. After 8 weeks, no difference in bone ingrowth was found between the OP-1 groups and their controls. It was only in the allografts that the addition of OP-1 resulted in more fibrous tissue ingrowth.
INTERPRETATION: We conclude that the previously observed delay in fibrous tissue ingrowth can be only partially overcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17966011     DOI: 10.1080/17453670710014211

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  1 in total

1.  Strontium doping of bone graft extender.

Authors:  Marianne T Vestermark; Ellen-Margrethe Hauge; Kjeld Soballe; Joan E Bechtold; Thomas Jakobsen; Jorgen Baas
Journal:  Acta Orthop       Date:  2011-09-06       Impact factor: 3.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.